Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens

Journal of Virology

Volumn 78, Issue 18, 2004, Pages 9624-9632

  Kang, Sang Moo ^a   Guo, Lizheng ^a   Yao, Qizhi ^b   Skountzou, Ioanna ^a   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA VIRUS; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS PARTICLE;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOKINES; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, INACTIVATED;

EID: 4444381770     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.18.9624-9632.2004     Document Type: Article

References (49)

1. Alfsen, A., P. Iniguez, E. Bouguyon, and M. Bomsel. 2001. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166:6257-6265.
2. Armerding, D., H. Rossiter, I. Ghazzouli, and E. Liehl. 1982. Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J. Infect. Dis. 145:320-330.
3. Behl, C., J. B. Davis, R. Lesley, and D. Schubert. 1994. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827.
4. Bender, A., L. K. Bui, M. A. Feldman, M. Larsson, and N. Bhardwaj. 1995. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J. Exp. Med. 182:1663-1671.
5. Blazevic, V., C. M. Trubey, and G. M. Shearer. 2000. Comparison of in vitro immunostimulatory potential of live and inactivated influenza viruses. Hum. Immunol. 61:845-849.
6. Brander, C., T. Wyss-Coray, D. Mauri, F. Bettens, and W. J. Pichler. 1993. Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide. Eur. J. Immunol. 23:3217-3223.
7. Brandtzaeg, P. 1989. Overview of the mucosal immune system. Curr. Top. Microbiol. Immunol. 146:13-25.
8. Chackerian, B., D. R. Lowy, and J. T. Schiller. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Investig. 108:415-423.
9. Compans, R. W. 1974. Hemagglutination-inhibition: rapid assay for neuraminic acid-containing viruses. J. Virol. 14:1307-1309.
10. Decker, T., and M. L. Lohmann-Matthes. 1988. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115:61-69.
11. Dong, M., P. F., Zhang, F. Grieder, J. Lee, G. Krishnamurthy, T. VanCott, C. Broder, V. R. Polonis, X. F. Yu, Y. Shao, D. Faix, P. Valente, and G. V. Quinnan, Jr. 2003. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J. Virol. 77:3119-3130.
12. Edinger, A. L., M. Ahuja, T. Sung, K. C. Baxter, B. Haggarty, R. W. Doms, and J. A. Hoxie. 2000. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J. Virol. 74:7922-7935.
13. Fuller, D. H., P. A. Rajakumar, L. A. Wilson, A. M. Trichel, J. T. Fuller, T. Shipley, M. S. Wu, K. Weis, C. R. Rinaldo, J. R. Haynes, and M. Murphey-Corb. 2002. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J. Virol. 76:3309-3317.
14. Gallichan, W. S., R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L. Davis, and K. L. Rosenthal. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:3451-3457.
15. Grunewald, S. M., C. Hahn, G. Wohlleben, M. Teufel, T. Major, H. Moll, E. B. Brocker, and K. J. Erb. 2002. Infection with influenza a virus leads to flu antigen-induced cutaneous anaphylaxis in mice. J. Investig. Dermatol. 118:645-651.
16. Guo, L., X. Lu, S. M. Kang, C. Chen, R. W. Compans, and Q. Yao. 2003. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313:502-513.
17. Hallenberger, S., S. P. Tucker, R. J. Owens, H. B. Bernstein, and R. W. Compans. 1993. Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology 193:510-514.
18. Hocini, H., L. Belec, S. Iscaki, B. Garin, J. Pillot, P. Becquart, and M. Bomsel. 1997. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res. Hum. Retrovir. 13:1179-1185.
19. Horner, A. A., A. Ronaghy, P. M. Cheng, M. D. Nguyen, H. J. Cho, D. Broide, and E. Raz. 1998. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 190:77-82.
20. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1992. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10:130-132.
21. Jones, D. H., B. W. McBride, M. A. Roff, and G. H. Farrar. 1995. Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies. Vaccine 13:991-999.
22. Jones, D. H., B. W. McBride, M. A. Roff, V. Maloney, and G. H. Farrar. 1994. Purification and characterization of simian immunodeficiency virus (SIV-mac) envelope glycoprotein gp130 from virus-infected cells. Vaccine 12:250-258.
23. Kang, S. M., and R. W. Compans. 2003. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J. Virol. 77:3615-3623.
24. Kaur, A., J. Yang, D. Hempel, L. Gritz, G. P. Mazzara, H. McClure, and R. P. Johnson. 2000. Identification of multiple simian immunodeficiency virus (SIV)-specific CTL epitopes in sooty mangabeys with natural and experimentally acquired SIV infection. J. Immunol. 164:934-943.
25. Korzeniewski, C., and D. M. Callewaert. 1983. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64:313-320.
26. Kretzchmar, E., R. Geyer, and H. D. Klenk. 1994. Baculovirus infection does not alter N-glycosylation in Spodoptera frugiperda cells. Biol. Chem. Hoppe Seyler 375:23-27.
27. Lagranderie, M., N. Winter, A. M. Balazuc, B. Gicquel, and M. Gheorghiu. 1998. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retrovir. 14:1625-1633.
28. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510-550.
29. Mazzoli, S., D. Trabattoni, C. S. Lo, S. Piconi, C. Ble, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, M. L. Fusi, N. Tofani, M. Biasin, M. L. Villa, F. Mazzotta, and M. Clerici. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1250-1257.
30. McCluskie, M. J., and H. L. Davis. 1999. CpG DNA as mucosal adjuvant. Vaccine 18:231-237.
31. McCluskie, M. J., and H. L. Davis. 2001. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19:413-422.
32. McLain, L., Z. Durrani, L. A. Wisniewski, C. Porta, G. P. Lomonossoff, and N. J. Dimmock. 1996. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 14:799-810.
33. Meyer, D., and J. V. Torres. 1999. Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs. Viral Immunol. 12:117-129,
34. Moldoveanu, Z., A. N. Vzorov, W. Q. Huang, J. Mestecky, and R. W. Compans. 1999. Induction of immune responses to SIV antigens by mucosally administered vaccines. AIDS Res. Hum. Retrovir. 15:1469-1476.
35. Moran, T. M., H. Park, A. Fernandez-Sesma, and J. L. Schulman. 1999. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J. Infect. Dis. 180:579-585.
36. Oran, A. E., and H. L. Robinson. 2003. DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells. J. Immunol. 171:1999-2005.
37. Paoletti, L. C., and R. C. Kennedy. 2002. Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3. J. Infect. Dis. 186:1597-1602.
38. Pinto, L. A., V. Blazevic, S. A. Anderson, D. J. Venzon, C. M. Trubey, T. Rowe, J. M. Katz, D. Liewehr, M. J. Dolan, and G. M. Shearer. 2001. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J. Infect. Dis. 183:1000-1008.
39. Rott, O., J. Charreire, and E. Cash. 1996. Influenza A virus hemagglutinin is a B cell-superstimulatory lectin. Med. Microbiol. Immunol. (Berlin) 184:185-193.
40. Rott, O., J. Charreire, M. Semichon, G. Bismuth, and E. Cash. 1995. B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKC-activating, Ca(2+)-independent mechanism. J. Immunol. 154:2092-2103.
41. Sha, Z., and R. W. Compans. 2000. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J. Virol 74:4999-5005.
42. Takada, A., S. Matsushita, A. Ninomiya, Y. Kawaoka, and H. Kida. 2003. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218.
43. Tamura, S., Y. Ito, H. Asanuma, Y. Hirabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, and T. Kurata. 1992. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:981-988.
44. Tamura, S. I., H. Asanuma, Y. Ito, Y. Hirabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, T. Kurata, and A. Oya. 1992. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol. 22:477-481.
45. Tegerstedt, K., K. Andreasson, A. Vlastos, K. O. Hedlund, T. Dalianis, and T. Ramqvist. 2003. Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J. Gen. Virol. 84:3443-3452.
46. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
47. Wilson, L. A., M. Murphey-Corb, L. N. Martin, R. M. Harrison, M. S. Ratterree, and R. P. Bohm. 2000. Identification of SIV env-specific CTL in the jejunal mucosa in vaginally exposed, seronegative rhesus macaques (Macaca mulatta). J. Med. Primatol. 29:173-181.
48. Yao, Q., F. M. Kuhlmann, R. Eller, R. W. Compans, and C. Chen. 2000. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res. Hum. Retrovir. 16:227-236.
49. Zheng, P., and Y. Liu. 1997. Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T cell activation. J. Exp. Med. 186:1787-1791.